


Please type a plus sign (+) inside this box ? +

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)					
					
Sheet	1	of			
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY
rh	AA	5,635,370		HOCKFIELD, et al.	06-03-97
FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY
OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
lm	AB	DAY, "The structure and regulation of hyaluronan-binding proteins," Biochemical Society Transactions, 27(2):115-121 (1999)			
lm	AC	KNUDSON, et al., "Hyaluronan-binding proteins in development, tissue homeostasis, and disease," The FASEB Journal, 7(13):1233-1241 (1993)			
Examiner	RITA MITRA		Date Considered	4/5/04	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	1	of	1	Application Number	09/466,778
				Filing Date	December 20, 1999
				First Named Inventor	Gregg A. Hastings
				Art Unit	1653
				Examiner Name	R. Mitra
				Attorney Docket Number	PF487

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
RH	AG	WO01/81544-A2	11-01-2001	WEIGEL et al.		
RH	AH	WO02/086093-A2	10-31-2002	WEIGEL et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
RH	AI	POLITZ et al., "Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues," <i>Biochem. J.</i> 362:155-164 (2002).				
RH	AJ	ZHOU et al., "Purification and molecular identification of the human hyaluronan receptor for endocytosis," <i>Glycobiology</i> 13(5):339-349 (2003).				
RH	AK	OERTLI et al., "Mechanisms of hyaluronan-induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-KB and activating protein-1," <i>J of Immunology</i> 161:3431-7 (1998).				
RH	AL	TSIFRINA et al., "Identification and characterization of three cDNAs that encode putative novel hyaluronan-binding proteins, including an endothelial cell-specific hyaluronan receptor," <i>Am J Pathol</i> 155(5):1625-33 (1999).				
RH	AM	MCCARTY et al., "Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis," <i>Med Hypothesis</i> . 50(6):507-10 (1998).				
RH	AN	UEBELHART et al., "Effects of hyaluronic acid on cartilage degradation," <i>Curr Opin Rheumatol.</i> 11(5):427-35 (1999).				
RH	AO	NAOR et al., "CD44: structure, function, and association with the malignant process," <i>Adv Cancer Res.</i> 71:241-319 (1997).				
RH	AP	WISNEWSKI et al., "TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity," <i>Cytokine Growth Factor Rev.</i> 8(2):143-156 (1997).				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	RITA MITRA	Date Considered	4/5/04
--------------------	------------	-----------------	--------